Virus-like particle (VLP) of the HBV preS antigen

About

Introduction: Despite great progress in antiviral treatments, hepatitis B virus (HBV) infection is still a major global public health problem. Approximately 2 billion people have been infected worldwide during their lifetime, and more than 350 million are chronic carriers of the virus. HBV infection may cause acute and chronic hepatitis, which leads to incurable chronic liver problems and cancer. Current HBV vaccines on the market, which protect most people against HBV infection, contain only the S antigen. However, almost 5-10% people vaccinated with the available vaccines fail to mount an adequate antibody response to offer protection. This raises a dire need to develop novel and efficient prophylactic or therapeutic vaccines for HBV infection with lower nonresponse rates. Technology: A Georgia State University researcher and his collaborator have designed a novel prophylactic vaccine candidate by generating a virus-like particle (VLP) of the HBV preS antigen. The preS antigen on infectious HBV particles induces strong B and T cell responses and enhances the seroprotection rate by overcoming non-responsiveness to the conventional S antigen-only vaccines. These VLPs can be used alone or in combination with vaccines containing the hepatitis B surface antigen (HBsAg) to vaccinate subjects against HBV as well as to activate T cells for adoptive T cell therapy to eradicate HBV infected hepatocytes.